European Archives - Page 462 of 1138 - European Medical Journal

Retracted: Building on a Strong Foundation to Address a New Era to Help Protect Against Pneumococcal Disease

Ramirez noted that more than 100 pneumococcal serotypes have now been identified, which is most likely the result of increased…

NUVAXOVIDᵀᴹ dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) For Individuals 12 Years and Older

Learn about NUVAXOVIDᵀᴹ dispersion for injection COVID-19 vaccine (recombinant, adjuvanted) for individuals 12 Years and older.

Cutaneous Mucormycosis Co-infection in a Patient with COVID-19

A 54-year-old male tested positive in late February on a screening COVID-19 test performed after a family member’s test had become positive. A few weeks later, they presented to the emergency room at a different hospital centre with shortness of breath and fever.

Roundtable: behind the headlines of Inflation Reduction Act

Two US pricing experts dissect the implications of The Inflation Reduction for the pharma industry in this roundtable.

Updates from the European Society for Medical Oncology 2022 Congress

This week, Jonathan Sackier is joined by Arndt Vogel to discuss his role at ESMO and key themes in cancer care from the ESMO Congress.

Cell and gene therapy: a victim of its own success

Landmark science has led to an inundation of new transformative therapies, but is the cell and gene market at the point of saturation?

EMJ Urology 10 [Supplement 2] 2022

As part of the 37th Annual European Association of Urology (EAU) Congress, this symposium presented key data from the CLEAR study: a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (RCC) in the first-line (1L) setting.

Recent Advances in the First-Line Management of Advanced Renal Cell Carcinoma: Focus on the Role of Lenvatinib Plus Pembrolizumab Combination Treatment

As part of the 37th Annual European Association of Urology (EAU) Congress, this symposium presented key data from the CLEAR study: a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (RCC) in the first-line (1L) setting.

Recent Advances in the First-Line Management of Advanced Renal Cell Carcinoma: Focus on the Role of Lenvatinib Plus Pembrolizumab Combination Treatment

The 37th Annual European Association of Urology (EAU) Congress 2022 in Amsterdam, the Netherlands, where data from the CLEAR study, a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab combination therapy against sunitinib as first-line treatment in patients with advanced renal cell carcinoma, were presented.

Expert Insights into Paediatric Tuberculosis

The first podcast in this three-part series introduces the topic of paediatric tuberculosis (TB) and the concept of latent TB infection (L TBI). Statistics on the risk of progression from LTBI to active TB, as well as the risk of severe TB disease, dissemination, and death in children versus adults are shared.